Objective:To study the polar chemical constituents of Blettila striata(Thunb.) Reichb.f. Methods:The constituents in N-butanol moiety were separated and purified by column chromatography with silica gel and SephadexLH-20, and were identified by spectral analysis. Results:Five compounds were identified as: militarine(1);7-hydroxy-4-methoxy-phenanthrene-2-O-?-D-glucoside(2);4-methoxyphenanthrene-2,7-O-?-D-diglucoside(3);7-hydroxy-2,4-dimethoxyphenanthrene-3-O-glucoside(4);3′-hydroxy-5-methoxybibenzyl-3-O-?-glucopyranoside(5). Conclusion:Compound 1,5 were isolated from this plant for the first time.

This study was aimed to investigate the clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B-cell lymphoma. A total of 88 patients with central nervous system diffuse large B-cell lymphoma was selected, out of them 54 patients received idarubicin combined with methotrexate and were selected as A group, other 34 patients received only methotrexate and were selected as B group (control group). Clinical efficacy and safety were compared after treatment. The results showed that in A group 84 patients achieved complete remission (CR), 5 patients archived partial remission (PR), the total remission rate of A group was 72.2%; in B group 10 patients achieved complete remission (CR), 4 patients archived partial remission (PR), the total remission rate of B group was 41.2%; the average survival time of A group was 33.172 months, and the average survival time of B group was 26.305 months, the former was significantly higher than latter (P < 0.05). It is concluded that idarubicin combined with methotrexate for the patients with central nervous system diffuse large B-cell lymphoma is effective and safe, and may be used in clinic.
Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Central Nervous System Neoplasms ; drug therapy ; Humans ; Idarubicin ; administration & dosage ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; Methotrexate ; administration & dosage ; Remission Induction ; Treatment Outcome

Aneurysm, False/etiology* ; Carotid Artery Injuries/therapy* ; Carotid Artery, Internal ; Embolization, Therapeutic ; Epistaxis/etiology* ; Humans

The ligation of dorsal venous complex (DVC) is a very important procedure during laparoscopic radical prostatectomy (LRP). Inaccurate DVC ligation may lead to severe bleeding or postoperative incontinence. We, therefore, designed the DVC pretightening technique to facilitate this procedure. The 32 involved patients with localized prostate cancer underwent LRP between July 2017 and October 2018. All of the patients received DVC pretightening technique. A laparoscopic intestinal clamp was used to narrow and strain DVC. The needle passage was limited between the bone and clamp. The ligation time, DVC-related blood loss, and continence data were recorded. The ligation of DVC in 32 patients was performed with DVC pretightening technique. Every suture was completed with one attempt. The mean ligation time was 2.7 ± 1.0 min. The DVC-related blood loss was 2.0 ± 1.3 ml. The 3-month continence rate was 81.3% (26/32). Positive margin rate was 9.4% (3/32). In conclusion, the DVC pretightening technique simplified the ligation of DVC during LRP. It is a safe and reliable technique. However, large-sample randomized controlled trials are still required to confirm the advantage of the new method in improving mean ligation time, DVC-related blood loss, continence rate, and positive margin rate.
Blood Loss, Surgical/prevention & control* ; Humans ; Laparoscopy/methods* ; Ligation/methods* ; Male ; Operative Time ; Prostate/surgery* ; Prostatectomy/methods* ; Treatment Outcome ; Veins/surgery*